EMPA-KIDNEY
Study of Heart and Kidney Protection with Empagliflozin
Doente / População Intervenção / Exposição Comparação Desfecho
In 6,609 patients across a broad spectrum of CKD, empagliflozin reduced kidney-disease progression or cardiovascular death compared with placebo.
N
6609
Desenho
Double-blind RCT, stopped early
Desfecho
CKD progression or cardiovascular death
Relevância
2
Resultado13.1% vs 16.9%; HR 0.72 (95% CI 0.64–0.82; p<0.001)
The EMPA-KIDNEY Collaborative Group. N Engl J Med. 2023;388(2):117-127. 10.1056/NEJMoa2204233
Discussão e crítica
Widest CKD eligibility yet (eGFR down to 20); no significant benefit in the UACR <30 mg/g subgroup.